

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

11/15/07

Substitute for form 1449/PTO

Complete if Known

Application Number	10/542,838
Filing Date	July 20, 2005
First Named Inventor	Willem Ferdinand Nieuwenhuizen
Art Unit	1615
Examiner Name	Eric E. Silverman
Attorney Docket Number	VER-194XX

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 6

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US- 5,190,876	03/02/1993	Kinkade Jr. et al.	
		US- 5,232,837	08/03/1993	Merrill, Jr. et al.	
		US- 5,374,616	12/20/1994	Spiegel et al.	
		US- 5,478,860	12/26/1995	Wheeler et al.	
		US- 5,519,007	05/21/1996	Della Valle et al.	
		US- 5,830,853	11/03/1998	Baekstroem et al.	
		US- 6,562,606	05/13/2003	Elias et al.	
		US- 6,610,835	08/26/2003	Liotta et al.	
		US- 2001/011,076	08/02/2001	Schwartz et al.	
		US- 2002/110,587	08/15/2002	Hope et al.	
		US- 2002/182,250	12/05/2002	Hori et al.	
		US- 2003/049,286	03/13/2003	Granger et al.	
		US- 2003/109,044	06/12/2003	Logan et al.	
		US- 2004/047,851	03/11/2004	Tabas et al.	
		US- 2004/063,667	04/01/2004	Kishikawa et al.	
		US- 2004/147,615	07/29/2004	Rinehart et al.	
		US- 2004/171,557	09/02/2004	Iian et al.	
		US- 2007/098,808	05/03/2007	Sampalis	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
		DE 196 02 108	07/24/1997	Beiersdorf AG		Abstract
		EP 0 373 038	06/13/1990	FIDIA S.p.A.		
		EP 0 988 860	03/29/2000	Kirin Beer Kabushiki Kaisha		
		EP 1 291 340	03/12/2003	Charmzone Co., Ltd.		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

11/15/07 Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/542,838
		Filing Date	July 20, 2005
		First Named Inventor	Willem Ferdinand Nieuwenhuizen
		Art Unit	1615
		Examiner Name	Eric E. Silverman
Sheet 2	of 6	Attorney Docket Number	VER-194XX

	EP 1 452 181	09/01/2004	Enzo Therapeutics, Inc.		
	FR 2 492 259 A	04/23/1982	Idinvex S.A.		
	FR 2 820 037 A	08/02/2002	Dermaconcept JMC		
	JP 11 269074	10/05/1999	Snow Brand Milk Prod. Co. Ltd.		Abstract
	JP 61 152632	07/11/1986	Dai Ichi Seiyaku Co. Ltd.		Abstract
	JP 63 044842 A	02/25/1998	KAO Corp.		Abstract
	JP 2000/350563	12/19/2000	Snow Brand Milk Prod. Co. Ltd.		Whole Document
	JP 2001/158735	06/12/2001	Snow Brand Milk Prod. Co. Ltd.		Whole Document
	JP 2001/158736	06/12/2001	Snow Brand Milk Prod. Co. Ltd.		Whole Document
	JP 2001 213858 A	08/07/2001	Sagami Chem. Res. Ct.; Taisho Pharma Co. Ltd.		Abstract
	JP 2002/226394	08/14/2002	Meiji Milk Prod. Co. Ltd.		Abstract
	JP 2002/068998	03/08/2002	Meiji Milk Prod. Co. Ltd.		Abstract
	JP 2003 137894	05/14/2003	Nat. Inst. Of Adv. Ind. & Technol.; Maruha Corp.		Abstract
	KR 2001 008 569 A - English Abstract Only	02/05/2001	Kwon Young Guen		Abstract Only
	WO 1992/03129	03/05/1992	Duke University		
	WO 1995/32002	11/30/1995	State of Oregon		
	WO 1997/11706 A	04/03/1997	George University		
	WO 1999/41266 A	08/19/1999	Emory University		
	WO 1999/61581	12/02/1999	Georgetown University Medical Center		
	WO 2000/50574	08/31/2000	Johns Hopkins University		
	WO 2001/60807	08/23/2001	Merck & Co. Inc.		
	WO 2001/72701	10/04/2001	The Liposome Company, Inc.		
	WO 2002/34062	05/02/2002	NV Marc Boone		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

11/15/07 Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/542,838
				Filing Date	July 20, 2005
				First Named Inventor	Willem Ferdinand Nieuwenhuizen
				Art Unit	1615
				Examiner Name	Eric E. Silverman
Sheet	3	of	6	Attorney Docket Number	VER-194XX

		WO 2002/102394	12/27/2002	Neptune Technologies & Bioresources Inc.		
		WO 2003/011873	02/13/2003	Neptune Technologies & Bioresources Inc.		
		WO 2003/088761	10/30/2003	Purpura et al.		
		WO 2003/096983	11/27/2003	Esperion Therapeutics, Inc.		
		WO 2004/016257	02/26/2004	Kim et al.		
		WO 2004/064819	08/05/2004	Nederlandse Organisatie Voor Toegepastnatuur-wetenschppelijk Onderzoek TNO		
		WO 2004/064820	08/05/2004	Nederlandse Organisatie Voor Toegepastnatuur-wetenschppelijk Onderzoek TNO		
		WO 2004/064823	08/05/2004	Aston University		
		WO 2004/096140	11/11/2004	The Penn State Research Foundation		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

11/15/07 Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/542,838
		Filing Date	July 20, 2005
		First Named Inventor	Willem Ferdinand Nieuwenhuizen
		Art Unit	1615
		Examiner Name	Eric E. Silverman
Sheet 4	of 6	Attorney Docket Number	VER-194XX

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Auge, Nathalie et al.: "Sphingomyelin metabolites in vascular cell signaling and atherogenesis" PROGRESS IN LIPID RESEARCH, vol. 39, no. 3, May 2000 (2000-05), pages 207-229.	
		Beers, M.H. and R. Berkow: "The Merck Manual of Diagnosis and Therapy, seventeenth edition" 1999, MERCK RESEARCH LABORATORIES, WHITEHOUSE STATION, N.J., XP002311213 page 1655, column 1, paragraph 4 - page 1656, column 1, paragraph 3.	
		Beers, M.H. and R. Berkow: "The Merck Manual of Diagnosis and Therapy, seventeenth edition" 1999, MERCK RESEARCH LABORATORIES, WHITEHOUSE STATION, N.J., XP002341450 page 1062; tables 148-4.	
		Bibel, D. J. et al.: "ANTIMICROBIAL ACTIVITY OF SPHINGOSINES" JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 98, no. 3, 1992, pages 269-273.	
		Bischoff, A. et al.: "Sphingosine-1-Phosphate and sphingosylphosphorylcholine constrict renal and mesenteric microvessels in vitro" BRITISH JOURNAL OF PHARMACOLOGY, BASINGSTOKE, HANTS, GB, vol. 130, no. 8, August 2000 (2000-08), pages 1871-1877.	
		Chatterjee, Subroto: "Sphingolipids in atherosclerosis and vascular biology" ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, vol. 18, no. 10, October 1998 (1998-10), pages 1523-1533.	
		Chong, P.H. et al.: "Atorvastatin calcium: an addition to HMG-CoA reductase inhibitors." Pharmacotherapy, vol. 17(6), pages 1157-1177; 1997.	
		Chung, N. et al.: "Phytosphingosine as a specific inhibitor of growth and nutrient import in Saccharomyces cerevisiae." THE JOURNAL OF BIOLOGICAL CHEMISTRY. UNITED STATES 21 SEP 2001, vol. 276, no. 38, 21 September 2001 (2001-09-21), pages 35614-35621.	
		Davaille et al. 2000. J. Biol. Chem., vol. 275, no. 44, pages 34628-34633.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

11/15/07 Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/542,838
		Filing Date	July 20, 2005
		First Named Inventor	Willem Ferdinand Nieuwenhuizen
		Art Unit	1615
		Examiner Name	Eric E. Silverman
Sheet 5	of 6	Attorney Docket Number	VER-194XX

		Fantini, J. et al.: "Synthetic Soluble Analogs of Galactosylceramide (GalCer) Bind to the V3 Domain of HIV-1 gp120 and Inhibit HIV-1-induced Fusion and Entry" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 11, 1997, pages 7245-7252.	
		Howell et al. 2002. Current Organic Chemistry, vol. 6, no. 4, 2002, pages 365-391.	
		Jiang, Xian-Cheng et al.: "Plasma sphingomyelin level as a risk factor for coronary artery disease" ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, vol. 20, no. 12, December 2000 (2000-12), pages 2614-2618.	
		Jung et al. 1996. Journal of Natural Products, vol. 59, no. 3, pages 319-322.	
		Kim, et al. 2000. Phytotherapy Res., 14(6), 448-451.	
		Leventhal, A. R. et al.: "Acid sphingomyelinase-deficient macrophages have defective cholesterol trafficking and efflux." THE JOURNAL OF BIOLOGICAL CHEMISTRY. 30 NOV 2001, vol. 276, no. 48, 30 November 2001 (2001-11-30), pages 44976-44983.	
		Mei Jie et al.: "C ₂ - CEramide influences the expression and insulin-mediated regulation of cyclic nucleotide phosphodiesterase 3B and lipolysis in 3T3-l1 adipocytes." Diabetes, vol. 51(3), pages 631-637; 2002.	
		Merrill Jr., A. H. et al.: "Role of dietary sphingolipids and inhibitors of sphingolipid metabolism in cancer and other diseases" JOURNAL OF NUTRITION 1995 UNITED STATES, vol. 125, no. 6 SUPPL., 1995, pages 1677S-1682S.	
		Ortenberg et al: Farmakologiya i Toksikologiya (Moscow), vol. 47, no. 4, 1984, pages 102-105.	
		Rueda, R. et al.: "Addition of gangliosides to an adapted milk formula modifies levels of fecal Escherichia coli in preterm newborn infants" J. PEDIATR., vol. 133, 1998, pages 90-94.	
		Schmelz, E. M. et al.: "Sphingomyelin consumption suppresses aberrant colonic crypt foci and increases the proportion of adenomas versus adenocarcinomas in cf1 mice treated with 1,2-dimethylhydrazine: implications for dietary sphingolipids and colon carcinogenesis" CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 56, no. 21, 1 November 1996 (1996-11-01), pages 4936-4941.	
		Sosnowski et al. 1997. Journal of Urology, vol. 158, no. 1, pages 269-274.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

11/15/07 Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/542,838
		Filing Date	July 20, 2005
		First Named Inventor	Willem Ferdinand Nieuwenhuizen
		Art Unit	1615
		Examiner Name	Eric E. Silverman
Sheet 6	of 6	Attorney Docket Number	VER-194XX

		Sprong, R.C. et al.: "Bovine milk fat components inhibit food-borne pathogens." International Dairy Journal, vol. 12, pages 209-215, 2002.	
		Thurman et al. 1994. Transplant Int.: Off. J. Eur. Soc. For Organ Transplantation. 1994, vol. 7 suppl 1, 1994, pages s167-s170.	
		Turinsky J et al: "Effect of sphingoid bases on basal and insulin-induced glucose uptake by skeletal muscle", JOURNAL OF CELL BIOLOGY, vol. 115, no. 3 PART 2, 1991, page 222A; & abstracts of papers presented at the thirty-first annual meeting of the american society for cell bi	
		Van Veldhoven Paul P et al: "Do sphingoid bases interact with the peroxisome proliferator activated receptor alpha (PPAR-alpha)?" ; CELLULAR SIGNALING, vol. 12, no. 7, July 2000 (2000-07), pages 475-479, page 477, column 2, lines 13-29	
		Vesper, H. et al.: "Sphingolipids in Food and the Emerging Importance of Sphingolipids to Nutrition" JOURNAL OF NUTRITION, vol. 129, 1999, pages 1239-1250.	
		Viola, G. et al.: "Absorption and distribution of arachidonate in rats receiving lysophospholipids by oral route" JOURNAL OF LIPID RESEARCH, BETHESDA, MD, US, vol. 34, no. 11, 1993, pages 1843-1852.	
		Yamada, T. et al.: "Growth inhibition of pancreatic cancer cells by sphingosylphosphorylcholine and influence of culture conditions" CMLS, Cell. mol. life. sci. vol. 53, pages 435-441, 1997.	
		Zheng et al. 2002. Hepatology, vol. 36, no. 4 part 2, page 215a. Abstract no. 196.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.